natgillin/translations-raw huggingface dataset:
Adjusted mean change from baseline was 3.8 for etanercept treated (n = 95) versus 0.8 for placebo treated (n = 105) patients (p &lt; 0.001).
Prilagojena povprečna sprememba od izhodišča je bila 3,8 pri bolnikih, zdravljenih z etanerceptom (n = 95), in 0,8 pri bolnikih, ki so prejemali placebo (n = 105) (p &lt; 0,001).
adjusted rate b p &lt; 0.001, Humira vs. placebo
korigiran za center. b p &lt; 0,001, zdravilo Humira v primerjavi s placebom
Adjustment of the starting Abraxane dose is not required for patients with mild to moderate renal impairment (estimated creatinine clearance ≥30 to &lt; 90 ml/min).
Prilagajanje začetnega odmerka zdravila Abraxane ni potrebno pri bolnikih z blago do zmerno okvaro ledvic (ocenjeni očistek kreatinina ≥ 30 do &lt; 90 ml/min).
Adjustments of the daily dose of tenofovir disoproxil (as fumarate) 33 mg/g granules are recommended in patients with moderate (creatinine clearance 30-49 ml/min) or severe (creatinine clearance &lt; 30 ml/min) renal impairment based on modelling of single-dose pharmacokinetic data in HIV negative and non-HBV infected subjects with varying degrees of renal impairment, including end-stage renal disease requiring haemodialysis.
Prilagoditev dnevnega odmerka dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata) 33 mg/g zrnca se priporoča pri bolnikih z zmerno (očistek kreatinina 30-49 ml/min) ali hudo (očistek kreatinina &lt; 30 ml/min) ledvično okvaro, ki temelji na podatkih farmakokinetičnega modeliranja enkratnih odmerkov pri bolnikih, ki so HIV-negativni in niso okuženi z virusom HBV, z različnimi stopnjami ledvične okvare, vključno s končno fazo ledvične bolezni, zaradi katere je potrebna hemodializa.
Administration of capecitabine should be interrupted if treatment- related elevations in bilirubin of &gt; 3.0 x ULN or treatment-related elevations in hepatic aminotransferases (ALT, AST) of &gt; 2.5 x ULN occur.
Jemanje kapecitabina moramo prekiniti, če se pojavi zvišanje ravni bilirubina nad 3,0-kratno zgornjo referenčno vrednost ali če se poveča aktivnost jetrnih aminotransferaz (ALT, AST) nad 2,5-kratno zgornjo referenčno vrednost.
Administration of capecitabine should be interrupted if treatment-related elevations in bilirubin of &gt; 3.0 x ULN or treatment- related elevations in hepatic aminotransferases (ALT, AST) of &gt; 2.5 x ULN occur.
Jemanje kapecitabina moramo prekiniti, če se pojavi zvišanje ravni bilirubina nad 3,0-kratno zgornjo referenčno vrednost ali če se poveča aktivnost jetrnih aminotransferaz (ALT, AST) nad 2,5-kratno zgornjo referenčno vrednost.
Administration of capecitabine should be interrupted if treatment-related elevations in bilirubin of &gt; 3.0 x ULN or treatment-related elevations in hepatic aminotransferases (ALT, AST) of &gt; 2.5 x ULN occur.
Jemanje kapecitabina moramo prekiniti, če se pojavi zvišanje ravni bilirubina nad 3,0-kratno zgornjo referenčno vrednost ali če se poveča aktivnost jetrnih aminotransferaz (ALT, AST) nad 2,5-kratno zgornjo referenčno vrednost.
Administration of hydroxocobalamin was generally associated with a normalisation of blood pressure (systolic blood pressure &gt; 90 mmHg) in 17 of 21 patients (81%) who had low blood pressure (systolic blood pressure &gt; 0 and ≤ 90 mmHg) after exposure to cyanide.
Pri 17 od 21 bolnikov (81%), ki so imeli po izpostavljenosti cianidu nizek krvni tlak (sistolični krvni tlak &gt; 0 in ≤ 90 mmHg), je bila na splošno uporaba hidroksokobalamina povezana z normalizacijo krvnega tlaka (sistolični krvni tlak &gt; 90 mmHg).
Administration of KANUMA to infants with confirmed multiple-organ failure should be at the discretion of the treating physician.
Dajanje zdravila Kanuma dojenčkom (starim &lt; 6 mesecev) s potrjeno odpovedjo več organov je dovoljeno po presoji lečečega zdravnika.
Adolescents (12 &lt; 18 years)
Mladostniki (12
Adolescents (9- &lt; 18 years)
Mladostniki (9- &lt; 18 let)
Adolescents 12 to &lt; 18
Mladostniki 12 do &lt; 18
Adolescents aged 12 to &lt; 18 years: 50 mg of tigecycline every 12 hours for 5 to 14 days.
Mladostniki, stari od 12 do &lt; 18 let: 50 mg tigeciklina vsakih 12 ur, 5 do 14 dni.
Adolescents weighing &lt; 51 kg: the maximum recommended daily dose of INVEGA is 6 mg.
Mladostniki s telesno maso &lt; 51 kg: največji priporočeni dnevni odmerek zdravila INVEGA je 6 mg.
Adolescents(9- &lt; 18 years)
Mladostniki (9- &lt; 18 let)
ADRs are listed by system organ class (SOC) and frequency: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100) and rare (≥ 1/10,000 to &lt; 1/1,000).
(≥ 1/100 do &lt; 1/10), občasni (≥ 1/1.000 do &lt; 1/100) in redki (≥ 1/10.000 do &lt; 1/1.000).
ADRs to Aldurazyme reported during the Phase 3 study and its extension in a total of 45 patients age 5 years and older and treated up to 4 years are listed below using the following categories of frequency: very common (≥1/10); common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
Neželeni učinki zdravila Aldurazyme, o katerih so poročali v tretji fazi študije in njenem podaljšanju pri 45 bolnikih, starih 5 let in več ter zdravljenih do 4 leta, so razporejeni v spodnji preglednici po naslednjih kategorijah pogostosti: zelo pogosto (≥1/10); pogosto (≥1/100 do &lt; 1/10), občasno (≥1/1.000 do &lt; 1/100), redko (≥1/10.000 do &lt; 1/1.000), zelo redko ( &lt; 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adult ( &gt; 18 years)
Odrasli ( &gt; 18 let)
Adult and adolescent (≥ 12 to &lt; 18 years old and weighing ≥ 30 kg) patients who had a FEV1 percent predicted between 25% and 85% were enrolled.
Vključeni bolniki so bili odrasli in mladostniki (≥ 12 do &lt; 18 let s telesno maso ≥ 30 kg) s predvidenim odstotkom FEV1 med 25% in 85%.
Adult and adolescent (≥ 12 to &lt; 18 years old and weighing ≥ 30 kg) patients who had a FEV1 percent predicted between 25% and 85% were enrolled.
Vključeni bolniki so bili odrasli in mladostniki (≥ 12 do &lt; 18 let s telesno maso ≥ 30 kg, n = 28) s predvidenim odstotkom FEV1 med 25% in 85%.
Adult patients with creatinine clearance &lt; 50 ml/min, including haemodialysis patients
Odrasli bolniki z očistkom kreatinina &lt; 50 ml/min, vključno z bolniki na hemodializi
Adult patients with creatinine clearance &lt; 50 ml/min, including haemodialysis patients:
Odrasli bolniki z očistkom kreatinina &lt; 50 ml/min, vključno z bolniki na hemodializi
Adult patients with severe renal impairment (creatinine clearance of &lt; 30 mL/minute) and patients with End Stage Renal Disease (ESRD) or on haemodialysis should be administered Ribavirin Mylan 200 mg/day.
Odrasli bolniki s hudo okvaro ledvic (očistek kreatinina &lt; 30 ml/min) in bolniki s končno odpovedjo ledvic (ESRD – end stage renal disease) ali tisti na hemodializi morajo prejemati 200 mg zdravila Ribavirin Mylan na dan.
Adults ( &gt; 21 and &lt; 65 years old)
Odrasli (stari &gt; 21 in &lt; 65 let)
Adults &gt; 21 years
Odrasli, stari &gt; 21 let
Adults &gt; 30 years
Odrasli &gt; 30 let
Adults and adolescents aged from 12 to &lt; 18 years with bodyweight ≥ 33 kg: see Table 1.
Odrasli in mladostniki, stari od 12 do &lt; 18 let s telesno maso ≥ 33 kg: glejte preglednico 1.
Adults and children &gt; 6 year
Odrasli in otroci &gt; 6 let
Adults and elderly ( &gt; 65 years)
Odrasli in starejši ( &gt; 65 let)
Adults, adolescents or children ( &gt; 40 kg) who are able to swallow capsules may receive appropriate doses of Tamiflu capsules.
Odrasli, mladostniki ali otroci (težji od 40 kg), ki lahko pogoltnejo kapsule, lahko prejmejo ustrezen odmerek kapsul zdravila Tamiflu.
Advanced ovarian cancer or remaining tumour ( &gt; 1 cm) after initial surgery, in combination with cisplatin as first-line treatment.
napredovalega karcinoma jajčnikov ali preostalega tumorja ( &gt; 1 cm) po začetni operaciji, v kombinaciji s cisplatinom kot zdravljenje prvega izbora
Adverse drug reactions from post-marketing surveillance as spontaneously reported during a period in which an estimated &gt; 70 million patients were treated with celecoxib (various doses, durations, and indications).
Neželeni učinki zdravila med pomarketinškim spremljanjem, spontano prijavljeni v obdobju, med katerim je celekoksib po ocenah dobivalo &gt; 70 milijonov bolnikov (različni odmerki, trajanje in indikacije).
Adverse reaction frequencies are defined as: very common (≥1/10), common (≥1/100, &lt; 1/10), uncommon (≥1/1,000, &lt; 1/100), rare (≥1/10,000, &lt; 1/1,000) or very rare ( &lt; 1/10000).
Pogostnost neželenih učinkov je opredeljena na naslednji način: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do &lt; 1/10), občasni (≥ 1/1.000 do &lt; 1/100), redki (≥ 1/10.000 do &lt; 1/1.000) ali zelo redki ( &lt; 1/10.000).
Adverse reaction frequencies: Very common (≥1/10), Common (≥1/100 to &lt; 1/10), not known (cannot be estimated from the available data).
Pogostost neželenih učinkov: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do &lt; 1/10), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are listed according to the MedDRA frequency convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (1/1,000 to &lt; 1/100), rare (1/10,000 to &lt; 1/1,000) and not known (can not be estimated from available data).
Neželeni učinki so razvrščeni po pogostnosti glede na klasifikacijo MedDRA: zelo pogosti ( &gt; 1/10), pogosti ( &gt; 1/100 do &lt; 1/10), občasni ( &gt; 1/1.000 do &lt; 1/100), redki ( &gt; 1/10.000 do &lt; 1/1.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are listed according to the MedDRA frequency convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (1/1,000 to &lt; 1/100), rare (1/10,000 to &lt; 1/1,000) and not known (can not be estimated from available data).
Neželeni učinki so razvrščeni po pogostnosti glede na klasifikacijo MedDRA: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do &lt; 1/10), občasni (≥ 1/1.000 do &lt; 1/100), redki (≥ 1/10.000 do &lt; 1/1.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are listed below by MedDRA System Organ Class (SOC) and frequency categories using the standard convention: Very common (1/10), Common (1/100 to &lt; 1/10), and Uncommon (1/1,000 to &lt; 1/100).
Neželeni učinki spodaj so navedeni v skladu s klasifikacijo organskih sistemov MedDRA in z navedbo pogostnosti po standardni konvenciji: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do &lt; 1/10) in občasni (≥ 1/1.000 do &lt; 1/100).
Adverse reactions are listed below in Table 1 by system organ class and frequency (frequencies are defined as: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so našteti spodaj v preglednici 1 po organskih sistemih in pogostnosti (pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do &lt; 1/10); občasni (≥ 1/1.000 do &lt; 1/100); redki (≥ 1/10.000 do &lt; 1/1.000); zelo redki ( &lt; 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov)).
Adverse reactions are listed below using the following convention : very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Neželeni učinki so našteti po naslednjem pravilu: zelo pogosti (≥ 1/10), pogosti (≥1/100 do &lt; 1/10), občasni (≥1/1.000 do &lt; 1/100), redki (≥1/10.000 do &lt; 1/1.000), zelo redki ( &lt; 1/10.000); neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are listed below using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so našteti po naslednji razvrstitvi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do &lt; 1/10), občasni (≥ 1/1.000 do &lt; 1/100), redki (≥ 1/10.000 do &lt; 1/1.000), zelo redki ( &lt; 1/10.000), neznano (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are listed below using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so našteti po naslednji razvrstitvi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100, &lt; 1/10), občasni (≥ 1/1.000, &lt; 1/100), redki (≥ 1/10.000, &lt; 1/1.000), zelo redki ( &lt; 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are listed by MedDRA body system organ class and by frequency: Very common (_≥1/10); Common (≥1/100 to &lt; 1/10); and Uncommon (≥ 1/1,000 to &lt; 1/100).
Neželeni učinki so navedeni po MedDRA klacifikaciji glede na organski sistem in pogostnost: zelo pogosti (≥1/10); pogosti (≥1/100 do &lt; 1/10), ter občasni (≥1/1,000 do &lt; 1/100).
Adverse reactions are listed by system organ class and frequency (common (1/100 to &lt; 1/10), uncommon (1/1,000 to &lt; 1/100) and rare (1/10,000 to &lt; 1/1,000)) in the table below.
V spodnji preglednici so neželeni učinki navedeni po organskih sistemih in pogostosti (pogosti (1/100 do &lt; 1/10), občasni (1/1.000 do &lt; 1/100) in redki (1/10.000 to &lt; 1/1.000)).
Adverse reactions are listed by system organ class and frequency (very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100) and rare (≥1/10,000 to &lt; 1/1,000)).
Opisani neželeni učinki so navedeni spodaj po organskem sistemu in pogostnosti (zelo pogosti (≥1/10), pogosti (≥1/100 do &lt; 1/10), občasni (≥1/1.000 do &lt; 1/100) &gt; in redki (≥1/10.000 do &lt; 1/1.000)).
Adverse reactions are listed by system organ class and frequency: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100) and rare (≥1/10,000 to 1/1,000).
Neželeni učinki so navedeni po organskih sistemih in pogostnosti: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do &lt; 1/10), občasni (≥ 1/1.000 do &lt; 1/100) in redki (≥ 1/10.000 do 1/1.000).
Adverse reactions are presented according to the MedDRA System Organ Classification and frequency convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to
Neželeni učinki so skladno s terminologijo MedDRA razvrščeni po organskih sistemih in pogostnosti: zelo pogosti (≥1/10), pogosti (≥1/100 do &lt; 1/10), občasni (≥1/1.000 do &lt; 1/100), redki (≥1/10.000 do
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to
Neželeni učinki so navedeni po padajoči resnosti in njihova pogostnost je opredeljena takole: zelo pogosti: (≥ 1/10); pogosti: (≥ 1/100 do &lt; 1/10); občasni: (≥ 1/1.000 do
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000).
Neželeni učinki so navedeni po padajoči resnosti in njihova pogostnost je opredeljena takole: zelo pogosti: (≥1/10); pogosti: (≥1/100 do &lt; 1/10); občasni: (≥1/1.000 do &lt; 1/100); redki: (≥1/10.000 do &lt; 1/1.000) in zelo redki: ( &lt; 1/10.000).
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000)
Neželeni učinki so razporejeni po padajoči resnosti ter sledeči pogostnosti: zelo pogosti: (≥1/10); pogosti: (≥1/100 do &lt; 1/10); občasni: (≥1/1.000 do &lt; 1/100); redki: (≥1/10.000 do &lt; 1/1.000) in zelo redki: ( &lt; 1/10.000).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjega dogovora: zelo pogosti (≥1/10); pogosti (≥1/100 do &lt; 1/10); občasni (≥1/1.000 do &lt; 1/100); redki (≥1/10.000 do &lt; 1/1.000); zelo redki ( &lt; 1/10.000), neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥ 1/10), common (≥1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥1/10,000 to
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjih navedb: zelo pogosti (≥1/10); pogosti (≥1/100 do &lt; 1/10); občasni (≥1/1.000 do &lt; 1/100); redki (≥1/10.000 do
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjih navedb: zelo pogosti (≥1/10); pogosti (≥1/100 do &lt; 1/10); občasni (≥1/1.000 do &lt; 1/100); redki (≥1/10.000 do &lt; 1/1.000); zelo redki ( &lt; 1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjega dogovora: zelo pogosti (≥1/10); pogosti (≥1/100 do &lt; 1/10); občasni (≥ 1/1.000 do &lt; 1/100); redki (≥ 1/10.000 do
Adverse reactions are ranked according to system organ class, using the following convention:very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjega dogovora: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do &lt; 1/10), občasni (≥ 1/1.000 do &lt; 1/100), redki (≥ 1/10.000 do
Adverse reactions are ranked below using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Neželeni učinki so spodaj razvrščeni po naslednjem dogovoru: zelo pogosti (≥1/10); pogosti (≥1/100 do &lt; 1/10); občasni (≥1/1.000 do &lt; 1/100); redki (≥1/10.000 do &lt; 1/1.000); zelo redki ( &lt; 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are ranked by system organ class and frequency ([very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000)]).
Neželeni učinki so razvrščeni po organskem sistemu in pogostnosti ([zelo pogosti (≥1/10); pogosti (≥1/100 do 1/10); občasni (≥1/1.000 do &lt; 1/100); redki (≥1/10.000 do &lt; 1/1.000); zelo redki ( &lt; 1/10.000)]).
Adverse reactions are ranked under headings of frequency using the following conventions: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1000 to &lt; 1/100), rare (≥1/10000 to &lt; 1/1000), very rare ( &lt; 1/10000).
Neželeni učinki so navedeni glede na pogostnost ob upoštevanju sledečih dogovorov: zelo pogosti (≥1/10), pogosti (≥1/100 do &lt; 1/10), občasni (≥1/1.000 do &lt; 1/100), redki (≥1/10.000 do &lt; 1/1.000), zelo redki ( &lt; 1/10.000).
Adverse reactions are ranked under headings of frequency using the following conventions: very common (≥1/10), common (≥1/100, &lt; 1/10), uncommon (≥1/1000, &lt; 1/100), rare (≥1/10000, &lt; 1/1000), very rare ( &lt; 1/10000).
Neželeni učinki so navedeni glede na pogostnost ob upoštevanju sledečih dogovorov: zelo pogosti (≥1/10), pogosti (≥1/100 do &lt; 1/10), občasni (≥1/1.000 do &lt; 1/100), redki (≥1/10.000 do &lt; 1/1.000), zelo redki ( &lt; 1/10.000).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni glede na pogostnost, najprej najpogostejši, in to po naslednjem dogovoru: zelo pogosti (1/10), pogosti (1/100 do &lt; 1/10), občasni (1/1.000 do &lt; 1/100), redki (1/10.000 do &lt; 1/1.000), zelo redki ( &lt; 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni glede na pogostnost, najprej najpogostejši, in to po naslednjem dogovoru: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do &lt; 1/10); občasni (≥ 1/1.000 do &lt; 1/100); redki (≥ 1/10.000 do &lt; 1/1.000); zelo redki ( &lt; 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni glede na pogostnost, najprej najpogostejši, in to po naslednjem dogovoru: zelo pogosti ( 1/10), pogosti ( 1/100 do &lt; 1/10), občasni ( 1/1.000 do &lt; 1/100), redki ( 1/10.000 do &lt; 1/1.000), zelo redki ( &lt; 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni po oznakah pogostnosti, najpogostejši najprej, upoštevaje naslednji dogovor: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do &lt; 1/10), občasni (≥ 1/1.000 do &lt; 1/100), redki (≥ 1/10.000 do &lt; 1/1.000), zelo redki ( &lt; 1/10.000), ni znano (ni mogoče oceniti na podlagi podatkov, ki so na voljo).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data, since no valid estimate can be derived from clinical trials or epidemiological studies).
V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti po naslednjem dogovoru: Zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do &lt; 1/10); občasni (≥ 1/1.000 do &lt; 1/100); redki (≥ 1/10.000 do &lt; 1/1.000); zelo redki ( &lt; 1/10.000), neznani (ni jih možno oceniti z razpoložljivimi podatki, saj ustrezna ocena iz kliničnih preskušanj ali epidemioloških študij ni mogoča).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (1/10), common (1/100 to &lt; 1/10), uncommon (1/1,000 to &lt; 1/100), rare (1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni glede na pogostnost, najprej najpogostejši, in to po naslednjem dogovoru: zelo pogosti (1/10), pogosti (1/100 do &lt; 1/10), občasni (1/1.000 do &lt; 1/100), redki (1/10.000 do &lt; 1/1.000), zelo redki ( &lt; 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).